ArticleHereditas2025
Hsa_circ_0071271 affected the progression of non-small cell lung cancer through miR-23a-5p.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer ranks among the most prevalent malignancies globally, with non-small cell lung cancer (NSCLC) constituting the predominant subtype. Currently, there are limitations in the treatment options and prognostic evaluation for NSCLC. Hsa_circ_0071271, a non-coding RNA, has an unclear expression and mechanism in NSCLC treatment. In this study, the impacts of hsa_circ_0071271 on NSCLC progression/prognosis and the possible mechanism of its inhibitory role in NSCLC progression through miR-23a-5p were investigated.
methodsThis investigation employed RT-qPCR to initially determine the expression levels of hsa_circ_0071271 in NSCLC tissues and cell lines. To evaluate the clinical significance of hsa_circ_0071271, ROC curve analysis, Kaplan-Meier survival analysis, and Cox regression were conducted. The impact of hsa_circ_0071271 knockdown on NSCLC cell lines A549 and CALU3 was examined through CCK-8 assays, flow cytometry, and transwell assays, corresponding to cell proliferation, apoptosis, and migration/invasion. The dual-luciferase reporter assay was used to examine the relationships between miR-23a-5p and hsa_circ_0071271, as well as between PTEN and miR-23a-5p. Pearson correlation analysis was conducted to assess the correlation between PTEN and miR-23a-5p. Subsequent experiments with CCK-8, flow cytometry, and transwell assays were carried out to explore how hsa_circ_0071271 regulates miR-23a-5p/PTEN and thereby affects NSCLC cell proliferation, apoptosis, migration, and invasion.
resultsHsa_circ_0071271 was expressed highly in NSCLC tissues and multiple cell lines. Hsa_circ_0071271 effectively distinguishes tumor tissues from normal ones and is associated with patient survival rates. Knocking down hsa_circ_0071271 inhibits NSCLC cell proliferation and migration/invasion while promoting apoptosis. The study also revealed an interaction between hsa_circ_0071271 and miR-23a-5p, as well as between PTEN and miR-23a-5p, with their expression levels showing a significant negative correlation. Further experiments indicated that hsa_circ_0071271 regulates miR-23a-5p/PTEN to suppress NSCLC cell proliferation, migration, and invasion and promote apoptosis.
conclusionsRegulating miR-23a-5p/PTEN by hsa_circ_0071271 knockdown has been found to inhibit NSCLC cell proliferation, migration and invasion, as well as promote apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.